Cargando…

Designer Oncolytic Adenovirus: Coming of Age

The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, Alexander T., Aguirre-Hernández, Carmen, Halldén, Gunnel, Parker, Alan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025169/ https://www.ncbi.nlm.nih.gov/pubmed/29904022 http://dx.doi.org/10.3390/cancers10060201

Ejemplares similares

Oncolytic adenovirus-mediated therapy for prostate cancer
por: Sweeney, Katrina, et al.
Publicado: (2016)

Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses
por: Green-Tripp, Gabriela, et al.
Publicado: (2022)

Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy
por: Aguirre-Hernández, Carmen, et al.
Publicado: (2018)

Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models
por: Man, Yang Kee Stella, et al.
Publicado: (2022)

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2015)

HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models
por: Rodríguez, María Del Carmen Rodríguez, et al.
Publicado: (2022)

The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11
por: Pantelidou, Constantia, et al.
Publicado: (2016)

Systemic delivery and SPECT/CT in vivo imaging of (125)I-labelled oncolytic adenoviral mutants in models of pancreatic cancer
por: Stella Man, Y. K., et al.
Publicado: (2019)

Oncolytic Adenoviruses in Gastrointestinal Cancers
por: Yokoda, Raquel T., et al.
Publicado: (2018)

Oncolytic Adenoviruses in Cancer Treatment
por: Alemany, Ramon
Publicado: (2014)

Oncolytic Adenovirus in Cancer Immunotherapy
por: Peter, Malin, et al.
Publicado: (2020)

Oncolytic Adenoviruses for Cancer Therapy
por: Tripodi, Lorella, et al.
Publicado: (2021)

Concepts in Oncolytic Adenovirus Therapy
por: Mantwill, Klaus, et al.
Publicado: (2021)

A Renaissance for Oncolytic Adenoviruses?
por: Blanchette, Paola, et al.
Publicado: (2023)

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer
por: Ingemarsdotter, C K, et al.
Publicado: (2010)

Increasing the Efficacy of Oncolytic Adenovirus Vectors
por: Toth, Karoly, et al.
Publicado: (2010)

Adenovirus as a Vector and Oncolytic Virus
por: Matsunaga, Wataru, et al.
Publicado: (2023)

Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
por: Hajeri, Praveensingh B., et al.
Publicado: (2020)

Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy
por: Hensen, Lobke C.M., et al.
Publicado: (2020)

The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses
por: Tate, Sophia J., et al.
Publicado: (2021)

Oncolytic Replication of E1b-Deleted Adenoviruses
por: Cheng, Pei-Hsin, et al.
Publicado: (2015)

Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts
por: Huang, Jing Li, et al.
Publicado: (2016)

Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy
por: Tan, Ee Wern, et al.
Publicado: (2022)

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
por: Zhao, Yaqi, et al.
Publicado: (2021)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Going viral: a review of replication-selective oncolytic adenoviruses
por: Larson, Christopher, et al.
Publicado: (2015)

Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma
por: Kiyokawa, Juri, et al.
Publicado: (2019)

Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer
por: Yang, Kaiyi, et al.
Publicado: (2022)

Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment
por: Gryciuk, Aleksander, et al.
Publicado: (2023)

Species D Adenoviruses as Oncolytic Viral Vectors
por: Bullard, Brianna L., et al.
Publicado: (2020)

A novel oncolytic adenovirus based on simian adenovirus serotype 24
por: Cheng, Tao, et al.
Publicado: (2017)

The Coming of Age of De Novo Protein Design
por: David, Baker
Publicado: (2021)

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
por: Abudoureyimu, Mubalake, et al.
Publicado: (2019)

Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?
por: Bots, Selas T.F., et al.
Publicado: (2020)

Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives
por: McKenna, Mary K., et al.
Publicado: (2020)

Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot
por: Oronsky, Bryan, et al.
Publicado: (2022)

Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials
por: Taylor, Isobel P., et al.
Publicado: (2023)

Photoactivatable oncolytic adenovirus for optogenetic cancer therapy
por: Hagihara, Yasuko, et al.
Publicado: (2020)

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region
por: Miranda, Enrique, et al.
Publicado: (2012)

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus
por: Hulin-Curtis, Sarah L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nkr852pv6i08sf1m1r5avm3t75